Fiduciary Alliance LLC Invests $811,000 in Thermo Fisher Scientific Inc. (NYSE:TMO)

Fiduciary Alliance LLC bought a new position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 1,558 shares of the medical research company's stock, valued at approximately $811,000.

A number of other hedge funds have also recently made changes to their positions in TMO. Legacy Investment Solutions LLC acquired a new position in Thermo Fisher Scientific during the 3rd quarter valued at about $26,000. Peterson Financial Group Inc. acquired a new stake in Thermo Fisher Scientific during the third quarter worth about $27,000. HWG Holdings LP purchased a new position in Thermo Fisher Scientific during the second quarter worth approximately $50,000. RPg Family Wealth Advisory LLC purchased a new position in Thermo Fisher Scientific during the third quarter worth approximately $50,000. Finally, Teachers Insurance & Annuity Association of America purchased a new position in Thermo Fisher Scientific during the third quarter worth approximately $65,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Barclays decreased their target price on Thermo Fisher Scientific from $620.00 to $610.00 and set an "equal weight" rating on the stock in a research report on Wednesday, October 23rd. StockNews.com lowered Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research note on Monday, January 6th. TD Cowen boosted their price objective on Thermo Fisher Scientific from $656.00 to $686.00 in a research note on Tuesday, October 22nd. Stephens began coverage on Thermo Fisher Scientific in a research note on Tuesday, October 1st. They set an "overweight" rating and a $680.00 price objective on the stock. Finally, UBS Group raised Thermo Fisher Scientific to a "strong-buy" rating in a research note on Monday, September 16th. Five research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $648.95.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO traded up $1.97 during trading hours on Tuesday, reaching $557.49. The stock had a trading volume of 2,207,390 shares, compared to its average volume of 2,048,593. The firm has a market cap of $213.24 billion, a price-to-earnings ratio of 34.95, a PEG ratio of 3.54 and a beta of 0.76. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific Inc. has a fifty-two week low of $493.30 and a fifty-two week high of $627.88. The firm has a 50-day moving average of $529.92 and a 200-day moving average of $568.10.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, beating the consensus estimate of $5.25 by $0.03. The firm had revenue of $10.60 billion during the quarter, compared to the consensus estimate of $10.63 billion. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The firm's revenue was up .2% compared to the same quarter last year. During the same period in the prior year, the business earned $5.69 EPS. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 21.68 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th will be paid a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a yield of 0.28%. The ex-dividend date of this dividend is Friday, December 13th. Thermo Fisher Scientific's dividend payout ratio is presently 9.78%.

Thermo Fisher Scientific announced that its Board of Directors has approved a share repurchase plan on Friday, November 15th that authorizes the company to buyback $4.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to reacquire up to 2% of its stock through open market purchases. Stock buyback plans are generally an indication that the company's board believes its shares are undervalued.

Insider Transactions at Thermo Fisher Scientific

In related news, SVP Michael A. Boxer sold 2,000 shares of the firm's stock in a transaction that occurred on Friday, October 25th. The stock was sold at an average price of $560.16, for a total value of $1,120,320.00. Following the completion of the transaction, the senior vice president now directly owns 12,736 shares of the company's stock, valued at $7,134,197.76. This trade represents a 13.57 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $530.26, for a total value of $5,302,600.00. Following the sale, the chief executive officer now owns 111,192 shares in the company, valued at approximately $58,960,669.92. This trade represents a 8.25 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 47,150 shares of company stock valued at $25,954,465. Corporate insiders own 0.34% of the company's stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.